Ver­tex fi­nal­ly makes NICE with Eng­land's NHS on CF ther­a­pies, but runs in­to hic­cup with pre­clin­i­cal kid­ney drug da­ta

Days af­ter Ver­tex Phar­ma­ceu­ti­cals $VRTX se­cured a much ear­li­er-than-an­tic­i­pat­ed FDA ap­proval for its cys­tic fi­bro­sis cock­tail that cov­ers the ma­jor­i­ty of pa­tients — the drug­mak­er has fi­nal­ly reached a deal with au­thor­i­ties in Eng­land to cov­er the use of its cys­tic fi­bro­sis drugs on the Na­tion­al Health Ser­vice (NHS).

Ver­tex has been hag­gling with UK’s cost-ef­fec­tive­ness watch­dog NICE, which has re­fused to al­low the com­pa­ny’s CF med­i­cines on to Eng­land’s NHS un­til Ver­tex of­fers it a dis­count that would com­pel the agency to look fa­vor­ably up­on its cost-ef­fec­tive­ness.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.